Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?
We inquired the impact of reduced therapy discontinuation in diabetic macular edema (DME) on physician’s revenue considering anti-vascular endothelial growth factor (VEGF) monotherapy and its combination with Navilas treatment. Data were collected on injection frequency, treatment discontinuation an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2019-02-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.cn/en_publish/2019/2/20190224.pdf |
| _version_ | 1818176708499472384 |
|---|---|
| author | Jacob Menzler Aljoscha Neubauer Focke Ziemssen |
| author_facet | Jacob Menzler Aljoscha Neubauer Focke Ziemssen |
| author_sort | Jacob Menzler |
| collection | DOAJ |
| description | We inquired the impact of reduced therapy discontinuation in diabetic macular edema (DME) on physician’s revenue considering anti-vascular endothelial growth factor (VEGF) monotherapy and its combination with Navilas treatment. Data were collected on injection frequency, treatment discontinuation and reimbursement fees for DME treatment with anti-VEGF compared to anti-VEGF in combination with navigated laser. Based on these data an economic model was built to compare physicians revenue over a 5y period using either therapy for 4 European countries and the USA. Due to patients’ higher therapy adherence, physicians using navigated laser therapy with anti-VEGF generate similar or higher revenues compared to VEGF monotherapy in all analyzed countries. The use of Navilas decreases the patient’s injection burden at the same clinical outcome, while the physician’s revenue remained stable or increased. Therewith, therapy discontinuation in DME can be reduced using the combination therapy with Navilas. |
| first_indexed | 2024-12-11T20:20:29Z |
| format | Article |
| id | doaj.art-4a1ddf00689840cc864e3c4005690eb2 |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-12-11T20:20:29Z |
| publishDate | 2019-02-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-4a1ddf00689840cc864e3c4005690eb22022-12-22T00:52:05ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982019-02-0112234234510.18240/ijo.2019.02.24Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?Jacob Menzler0Aljoscha Neubauer1Focke Ziemssen2Institute for Health and Pharmacoeconomics, Muenchen 81739, GermanyInstitute for Health and Pharmacoeconomics, Muenchen 81739, Germany; Private Practice Ophthalmology, Muenchen 81739, GermanyCenter for Ophthalmology, Eberhard-Karls University, Tuebingen 72076, GermanyWe inquired the impact of reduced therapy discontinuation in diabetic macular edema (DME) on physician’s revenue considering anti-vascular endothelial growth factor (VEGF) monotherapy and its combination with Navilas treatment. Data were collected on injection frequency, treatment discontinuation and reimbursement fees for DME treatment with anti-VEGF compared to anti-VEGF in combination with navigated laser. Based on these data an economic model was built to compare physicians revenue over a 5y period using either therapy for 4 European countries and the USA. Due to patients’ higher therapy adherence, physicians using navigated laser therapy with anti-VEGF generate similar or higher revenues compared to VEGF monotherapy in all analyzed countries. The use of Navilas decreases the patient’s injection burden at the same clinical outcome, while the physician’s revenue remained stable or increased. Therewith, therapy discontinuation in DME can be reduced using the combination therapy with Navilas.http://www.ijo.cn/en_publish/2019/2/20190224.pdfdiabetic macular edemalaser therapynavilascost-effectivenessinjection burdenadherence |
| spellingShingle | Jacob Menzler Aljoscha Neubauer Focke Ziemssen Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? International Journal of Ophthalmology diabetic macular edema laser therapy navilas cost-effectiveness injection burden adherence |
| title | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
| title_full | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
| title_fullStr | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
| title_full_unstemmed | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
| title_short | Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses? |
| title_sort | navigated laser in diabetic macular edema the impact of reduced injection burden on patients and physicians who wins and who loses |
| topic | diabetic macular edema laser therapy navilas cost-effectiveness injection burden adherence |
| url | http://www.ijo.cn/en_publish/2019/2/20190224.pdf |
| work_keys_str_mv | AT jacobmenzler navigatedlaserindiabeticmacularedematheimpactofreducedinjectionburdenonpatientsandphysicianswhowinsandwholoses AT aljoschaneubauer navigatedlaserindiabeticmacularedematheimpactofreducedinjectionburdenonpatientsandphysicianswhowinsandwholoses AT fockeziemssen navigatedlaserindiabeticmacularedematheimpactofreducedinjectionburdenonpatientsandphysicianswhowinsandwholoses |